Alector Inc (ALEC) - Total Liabilities
Based on the latest financial reports, Alector Inc (ALEC) has total liabilities worth $262.59 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ALEC cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Alector Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Alector Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Alector Inc balance sheet assets.
Alector Inc Competitors by Total Liabilities
The table below lists competitors of Alector Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Seoyon E Hwa Co Ltd
KO:200880
|
Korea | ₩2.07 Trillion |
|
Froch Enterprise Co Ltd
TW:2030
|
Taiwan | NT$6.54 Billion |
|
Perma-Fix Environmental Svcs Inc
NASDAQ:PESI
|
USA | $38.71 Million |
|
Gamehost Inc.
TO:GH
|
Canada | CA$58.40 Million |
|
technotrans SE
F:TTR1
|
Germany | €57.07 Million |
|
Digital Imaging Technology INC
KQ:110990
|
Korea | ₩25.61 Billion |
|
Comstock Holding Companies Inc
NASDAQ:CHCI
|
USA | $10.98 Million |
|
CPE Technology Berhad
KLSE:5317
|
Malaysia | RM17.56 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Alector Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ALEC equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 8.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.90 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alector Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alector Inc (2016–2025)
The table below shows the annual total liabilities of Alector Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $262.59 Million | -23.11% |
| 2024-12-31 | $341.50 Million | -29.97% |
| 2023-12-31 | $487.67 Million | -14.92% |
| 2022-12-31 | $573.21 Million | +11.53% |
| 2021-12-31 | $513.93 Million | +132.84% |
| 2020-12-31 | $220.72 Million | -2.84% |
| 2019-12-31 | $227.17 Million | -44.01% |
| 2018-12-31 | $405.76 Million | +40.84% |
| 2017-12-31 | $288.09 Million | +264.59% |
| 2016-12-31 | $79.02 Million | -- |
About Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheim… Read more